Jes Olesen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5607907/publications.pdf Version: 2024-02-01



IFS OLESEN

#	Article	IF	CITATIONS
1	Preface to the Second Edition. Cephalalgia, 2004, 24, 9-10.	1.8	5,187
2	Large recurrent microdeletions associated with schizophrenia. Nature, 2008, 455, 232-236.	13.7	1,619
3	Epidemiology of headache in a general population—A prevalence study. Journal of Clinical Epidemiology, 1991, 44, 1147-1157.	2.4	1,300
4	Cost of disorders of the brain in Europe 2010. European Neuropsychopharmacology, 2011, 21, 718-779.	0.3	1,253
5	Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine. New England Journal of Medicine, 2004, 350, 1104-1110.	13.9	1,118
6	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	6.0	1,085
7	Focal hyperemia followed by spreading oligemia and impaired activation of rcbf in classic migraine. Annals of Neurology, 1981, 9, 344-352.	2.8	893
8	Vestibular migraine: Diagnostic criteria. Journal of Vestibular Research: Equilibrium and Orientation, 2012, 22, 167-172.	0.8	787
9	Cost of disorders of the brain in Europe. European Journal of Neurology, 2005, 12, 1-27.	1.7	714
10	Regional Cerebral Blood Flow in Man Determined by the Initial Slope of the Clearance of Intra-arterially Injected I33Xe. Stroke, 1971, 2, 519-540.	1.0	553
11	Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Annals of Neurology, 1990, 28, 791-798.	2.8	538
12	Migraine With Aura and Migraine Without Aura: An Epidemiological Study. Cephalalgia, 1992, 12, 221-228.	1.8	535
13	Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nature Genetics, 2016, 48, 856-866.	9.4	520
14	Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurology, The, 2009, 8, 679-690.	4.9	458
15	A nosographic analysis of the migraine aura in a general population. Brain, 1996, 119, 355-361.	3.7	425
16	Prevalence and Sex-Ratio of the Subtypes of Migraine. International Journal of Epidemiology, 1995, 24, 612-618.	0.9	400
17	Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia, 2010, 30, 1179-1186.	1.8	365
18	Pressure-pain threshold in human temporal region. Evaluation of a new pressure algometer. Pain, 1986, 25, 313-323.	2.0	362

#	Article	IF	CITATIONS
19	PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain, 2009, 132, 16-25.	3.7	360
20	REGIONAL CEREBRAL BLOOD FLOW DURING MIGRAINE ATTACKS BY XENON-133 INHALATION AND EMISSION TOMOGRAPHY. Brain, 1984, 107, 447-461.	3.7	353
21	Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain, 1989, 38, 17-24.	2.0	340
22	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurology, The, 2014, 13, 1100-1107.	4.9	333
23	Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nature Genetics, 2010, 42, 869-873.	9.4	332
24	Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. NeuroReport, 1993, 4, 1027-1030.	0.6	296
25	A Population-Based Analysis of the Diagnostic Criteria of the International Headache Society. Cephalalgia, 1991, 11, 129-134.	1.8	281
26	Pericranial Tenderness in Tension Headache: A Blind, Controlled Study. Cephalalgia, 1987, 7, 249-255.	1.8	275
27	Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain, 2003, 126, 241-247.	3.7	272
28	Muscle tenderness and pressure pain thresholds in headache. A population study. Pain, 1993, 52, 193-199.	2.0	270
29	The International Classification of Headache Disorders. Headache, 2008, 48, 691-693.	1.8	254
30	CONTRALATERAL FOCAL INCREASE OF CEREBRAL BLOOD FLOW IN MAN DURING ARM WORK. Brain, 1971, 94, 635-646.	3.7	253
31	Evidence for a vascular factor in migraine. Annals of Neurology, 2011, 69, 635-645.	2.8	252
32	Clinical and pathophysiological observations in migraine and tension-type headache explained by integration of vascular, supraspinal and myofascial inputs. Pain, 1991, 46, 125-132.	2.0	245
33	Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurology, The, 2013, 12, 454-461.	4.9	244
34	The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. , 2008, 120, 157-171.		243
35	Sodium valproate has a prophylactic effect in migraine without aura. Neurology, 1994, 44, 647-647.	1.5	242
36	Nitric oxide is a key molecule in migraine and other vascular headaches. Trends in Pharmacological Sciences, 1994, 15, 149-153.	4.0	239

#	Article	IF	CITATIONS
37	Trigeminal Neuralgia – A Prospective Systematic Study of Clinical Characteristics in 158 Patients. Headache, 2014, 54, 1574-1582.	1.8	226
38	Presentation of a New Instrument: The Diagnostic Headache Diary. Cephalalgia, 1992, 12, 369-374.	1.8	220
39	Questionnaire Versus Clinical Interview in the Diagnosis of Headache. Headache, 1991, 31, 290-295.	1.8	215
40	Evidence of a genetic factor in migraine with aura: A population-based Danish twin study. Annals of Neurology, 1999, 45, 242-246.	2.8	210
41	Cephalic muscle tenderness and pressure pain threshold in a general population. Pain, 1992, 48, 197-203.	2.0	200
42	Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain, 2014, 137, 779-794.	3.7	196
43	Regional cerebral blood flow studies in subarachnoid hemorrhage. Journal of Neurosurgery, 1972, 37, 36-44.	0.9	195
44	Muscular Factors are of Importance in Tension-Type Headache. Headache, 1998, 38, 10-17.	1.8	194
45	lschaemia-induced (symptomatic) migraine attacks may be more frequent than migraine-induced ischaemic insults. Brain, 1993, 116, 187-202.	3.7	191
46	Significance of neurovascular contact in classical trigeminal neuralgia. Brain, 2015, 138, 311-319.	3.7	191
47	The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. , 2009, 124, 309-323.		187
48	Pressure pain thresholds and thermal nociceptive thresholds in chronic tension-type headache. Pain, 1989, 38, 203-210.	2.0	186
49	No increase of calcitonin gene-related peptide in jugular blood during migraine. Annals of Neurology, 2005, 58, 561-568.	2.8	181
50	Qualitatively altered nociception in chronic myofascial pain. Pain, 1996, 65, 259-264.	2.0	179
51	International Classification of Headache Disorders. Lancet Neurology, The, 2018, 17, 396-397.	4.9	171
52	Human models of migraine — short-term pain for long-term gain. Nature Reviews Neurology, 2017, 13, 713-724.	4.9	165
53	Arterial Supersensitivity to Nitric Oxide (Nitroglycerin) in Migraine Sufferers. Cephalalgia, 1993, 13, 395-399.	1.8	161
54	BIBN4096BS Antagonizes Human α-calcitonin Gene Related Peptide–induced Headache and Extracerebral Artery Dilatation*. Clinical Pharmacology and Therapeutics, 2005, 77, 202-213.	2.3	159

#	Article	IF	CITATIONS
55	Probable medication-overuse headache: The effect of a 2-month drug-free period. Neurology, 2006, 66, 1894-1898.	1.5	155
56	The Cost of Brain Diseases: A Burden or a Challenge?. Neuron, 2014, 82, 1205-1208.	3.8	154
57	Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine. NeuroReport, 1995, 6, 1475-1479.	0.6	144
58	Some Clinical Features of the Acute Migraine Attack. An Analysis of 750 Patients. Headache, 1978, 18, 268-271.	1.8	141
59	Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nature Genetics, 2022, 54, 152-160.	9.4	135
60	The migraine postdrome. Neurology, 2016, 87, 309-313.	1.5	134
61	Leao's spreading depression in the hippocampus explains transient global amnesia. Acta Neurologica Scandinavica, 1986, 73, 219-220.	1.0	133
62	Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurology, The, 2009, 8, 718-723.	4.9	131
63	Chronic migraine—classification, characteristics and treatment. Nature Reviews Neurology, 2012, 8, 162-171.	4.9	130
64	Headache provocation by continuous intravenous infusion of histamine. Clinical results and receptor mechanisms. Pain, 1980, 8, 253-259.	2.0	125
65	Calcitonin gene-related peptide, neurokinin A and substance P: Effects on Nociception and neurogenic inflammation in human skin and temporal muscle. Peptides, 1991, 12, 333-337.	1.2	124
66	Evidence for a separate type of migraine with aura. Neurology, 2003, 60, 595-601.	1.5	123
67	Preface to the First Edition (1988). Cephalalgia, 2004, 24, 8-8.	1.8	122
68	Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: A systematic review. Cephalalgia, 2014, 34, 409-425.	1.8	119
69	Migraine without aura: A population-based twin study. Annals of Neurology, 1999, 46, 606-611.	2.8	116
70	Inheritance of migraine investigated by complex segregation analysis. Human Genetics, 1995, 96, 726-730.	1.8	115
71	Spreading Cerebral Oligemia in Classical- and Normal Cerebral Blood Flow in Common Migraine. Headache, 1982, 22, 242-248.	1.8	113
72	The Phosphodiesterase 5 Inhibitor Sildenafil Has No Effect on Cerebral Blood Flow or Blood Velocity, but Nevertheless Induces Headache in Healthy Subjects. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1124-1131.	2.4	113

#	Article	IF	CITATIONS
73	Evidence of qualitatively altered nociception in patients with fibromyalgia. Arthritis and Rheumatism, 1997, 40, 98-102.	6.7	112
74	Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. British Journal of Pharmacology, 2004, 143, 697-704.	2.7	112
75	Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia, 2012, 32, 140-149.	1.8	111
76	Evaluation of pericranial tenderness and oral function in patients with common migraine, muscle contraction headache and †combination headache'. Pain, 1982, 12, 385-393.	2.0	110
77	Nitric oxide in primary headaches. Current Opinion in Neurology, 2001, 14, 315-321.	1.8	109
78	Association between migraine, lifestyle and socioeconomic factors: a population-based cross-sectional study. Journal of Headache and Pain, 2011, 12, 157-172.	2.5	108
79	A comparison of tension-type headache in migraineurs and in non-migraineurs: a population-based study. Pain, 1996, 67, 501-506.	2.0	107
80	Provocation of migraine with aura using natural trigger factors. Neurology, 2013, 80, 428-431.	1.5	107
81	Co-morbidity of migraine with somatic disease in a large population-based study. Cephalalgia, 2011, 31, 43-64.	1.8	105
82	Migraine Without Aura and Migraine With Aura Are Distinct Disorders. A Population-Based Twin Survey. Headache, 2002, 42, 332-336.	1.8	103
83	Calcitonin Geneâ€Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class. Headache, 2019, 59, 951-970.	1.8	103
84	Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: Comparison with cerebral and temporal arteries. Peptides, 1992, 13, 527-536.	1.2	101
85	ICHD-3 beta is published. Use it immediately. Cephalalgia, 2013, 33, 627-628.	1.8	101
86	Nitric Oxide-Related Drug Targets in Headache. Neurotherapeutics, 2010, 7, 183-190.	2.1	100
87	Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38. Cephalalgia, 2012, 32, 337-345.	1.8	98
88	The PACAP Receptor: A Novel Target for Migraine Treatment. Neurotherapeutics, 2010, 7, 191-196.	2.1	97
89	Migraine induced by hypoxia: an MRI spectroscopy and angiography study. Brain, 2016, 139, 723-737.	3.7	97
90	Experimental muscle pain and tenderness following infusion of endogenous substances in humans. European Journal of Pain, 2003, 7, 145-153.	1.4	95

#	Article	IF	CITATIONS
91	Pericranial muscle tenderness and pressure-pain threshold in the temporal region during common migraine. Pain, 1988, 35, 65-70.	2.0	94
92	Basilar-type migraine: Clinical, epidemiologic, and genetic features. Neurology, 2006, 66, 880-886.	1.5	94
93	Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. Brain, 2019, 142, 2644-2654.	3.7	94
94	The Effect of Intra-arterial Papaverine on the Regional Cerebral Blood Flow in Patients with Stroke or Intracranial Tumor. Stroke, 1971, 2, 148-159.	1.0	93
95	Muscle palpation with controlled finger pressure: new equipment for the study of tender myofascial tissues. Pain, 1994, 59, 235-239.	2.0	92
96	Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. Pain, 2016, 157, 2773-2781.	2.0	90
97	Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries. Annals of Neurology, 1986, 20, 496-501.	2.8	89
98	Concomitant Persistent Pain in Classical Trigeminal Neuralgia – Evidence for Different Subtypes. Headache, 2014, 54, 1173-1183.	1.8	89
99	Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. Brain, 2014, 137, 2951-2959.	3.7	88
100	A Placebo-Controlled, Double-Blind, Cross-Over Trial of Flunarizine in Common Migraine. Cephalalgia, 1986, 6, 7-14.	1.8	84
101	Familial occurrence of migraine without aura and migraine with aura. Neurology, 1993, 43, 1369-1369.	1.5	84
102	Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience. Cephalalgia, 2013, 33, 540-553.	1.8	83
103	Effervescent Metoclopramide and Aspirin (Migravess) Versus Effervescent Aspirin or Placebo for Migraine Attacks: A Double-Blind Study. Cephalalgia, 1984, 4, 107-111.	1.8	82
104	Clinical Characterization of Patients with Chronic Tension Headache. Headache, 1988, 28, 590-596.	1.8	79
105	The Genetics of Migraine Without Aura and Migraine With Aura. Cephalalgia, 1993, 13, 245-248.	1.8	78
106	The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regulatory Peptides, 2007, 140, 185-191.	1.9	78
107	Clinical Characteristics of Migraine and Episodic Tension-Type Headache in Relation to Old and New Diagnostic Criteria. Headache, 1990, 30, 514-519.	1.8	75
108	Pain and tenderness in human temporal muscle induced by bradykinin and 5-hydroxytryptamine. Peptides, 1990, 11, 1127-1132.	1.2	75

#	Article	IF	CITATIONS
109	Quantitative Evaluation of Normal and Pathologic Cerebral Blood Flow Regulation to Perfusion Pressure. Archives of Neurology, 1973, 28, 143.	4.9	73
110	Methodological Aspects of Prophylactic Drug Trials in Migraine. Cephalalgia, 1981, 1, 127-141.	1.8	73
111	mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene–related peptide in the rat trigeminovascular system. Pain, 2012, 153, 830-838.	2.0	72
112	Calcitonin gene–related peptide does not cause the familial hemiplegic migraine phenotype. Neurology, 2008, 71, 841-847.	1.5	70
113	Tension-type headache: an update on mechanisms and treatment. Current Opinion in Neurology, 2000, 13, 285-289.	1.8	69
114	PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor. Neuropeptides, 2014, 48, 53-64.	0.9	69
115	Prostaglandin E ₂ induces immediate migraine-like attack in migraine patients without aura. Cephalalgia, 2012, 32, 822-833.	1.8	68
116	DBDS Genomic Cohort, a prospective and comprehensive resource for integrative and temporal analysis of genetic, environmental and lifestyle factors affecting health of blood donors. BMJ Open, 2019, 9, e028401.	0.8	68
117	The Phosphodiesterase 3 Inhibitor Cilostazol Dilates Large Cerebral Arteries in Humans without Affecting Regional Cerebral Blood Flow. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 1352-1358.	2.4	66
118	Characterization of consistent triggers of migraine with aura. Cephalalgia, 2011, 31, 416-438.	1.8	66
119	Nitric oxide synthase, calcitonin gene-related peptide and NK-1 receptor mechanisms are involved in GTN-induced neuronal activation. Cephalalgia, 2014, 34, 136-147.	1.8	66
120	Sumatriptan is a Potent Vasoconstrictor of Human Dural Arteries Via a 5-HT1-Like Receptor. Cephalalgia, 1992, 12, 202-205.	1.8	65
121	Emerging migraine treatments and drug targets. Trends in Pharmacological Sciences, 2011, 32, 352-359.	4.0	65
122	Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia, 2011, 31, 181-189.	1.8	65
123	Sulpiride and Paroxetine in the Treatment of Chronic Tension-Type Headache. An Explanatory Double-Blind Trial. Headache, 1994, 34, 20-24.	1.8	64
124	Predictors of outcome of the treatment programme in a multidisciplinary headache centre. Cephalalgia, 2010, 30, 1214-1224.	1.8	64
125	Cerebral Apoplexy (Stroke) Treated With or Without Prolonged Artificial Hyperventilation: 1. Cerebral Circulation, Clinical Course, and Cause of Death. Stroke, 1973, 4, 568-619.	1.0	63
126	Taking the Negative View of Current Migraine Treatments. CNS Drugs, 2012, 26, 375-382.	2.7	63

#	Article	IF	CITATIONS
127	Common Variant Burden Contributes to the Familial Aggregation of Migraine in 1,589 Families. Neuron, 2018, 98, 743-753.e4.	3.8	63
128	Tomographic Determination of Cerebral Blood Flow During Attacks of Cluster Headache. Cephalalgia, 1984, 4, 17-23.	1.8	61
129	Detoxification for medication overuse headache is the primary task. Cephalalgia, 2012, 32, 420-422.	1.8	61
130	Genetic analysis for a shared biological basis between migraine and coronary artery disease. Neurology: Genetics, 2015, 1, e10.	0.9	61
131	The Prevalence and Characteristics of Migraine in Twins From the General Population. Headache, 1999, 39, 173-180.	1.8	60
132	The relative influence of environment and genes in episodic tension-type headache. Neurology, 2004, 62, 2065-2069.	1.5	60
133	Differential expression of BK channel isoforms and β-subunits in rat neuro-vascular tissues. Biochimica Et Biophysica Acta - Biomembranes, 2009, 1788, 380-389.	1.4	59
134	Transcranial Doppler and cardiovascular responses during cardiovascular autonomic tests in migraineurs during and outside attacks. Brain, 1995, 118, 1319-1327.	3.7	57
135	Interhemispheric differences of fMRI responses to visual stimuli in patients with sideâ€fixed migraine aura. Human Brain Mapping, 2014, 35, 2714-2723.	1.9	57
136	PACAP27 induces migraine-like attacks in migraine patients. Cephalalgia, 2020, 40, 57-67.	1.8	57
137	New daily persistent headache: a systematic review on an enigmatic disorder. Journal of Headache and Pain, 2019, 20, 80.	2.5	56
138	Evaluation of Pericranial Myofascial Nociception by Pressure Algometry. Reproducibility and Factors of Variation. Cephalalgia, 1992, 12, 33-37.	1.8	53
139	The 5-HT1-Like Agonist Sumatriptan has a Significant Effect in Chronic Tension-Type Headache. Cephalalgia, 1992, 12, 375-379.	1.8	53
140	Prostaglandins in migraine. Current Opinion in Neurology, 2013, 26, 269-275.	1.8	53
141	Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. European Journal of Neurology, 1998, 5, 535-543.	1.7	52
142	Possible site of action of CGRP antagonists in migraine. Cephalalgia, 2011, 31, 748-750.	1.8	52
143	Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. European Journal of Neurology, 1998, 5, 469-477.	1.7	51
144	Proposed new diagnostic criteria for chronic migraine. Cephalalgia, 2020, 40, 399-406.	1.8	50

#	Article	IF	CITATIONS
145	EEG During Attacks of Common and Classical Migraine. Cephalalgia, 1981, 1, 63-66.	1.8	49
146	Calcitonin Geneâ€Related Peptide Does Not Cause Migraine Attacks in Patients With Familial Hemiplegic Migraine. Headache, 2011, 51, 544-553.	1.8	49
147	A genome-wide cross-phenotype meta-analysis of the association of blood pressure with migraine. Nature Communications, 2020, 11, 3368.	5.8	49
148	Epidemiology of migraine and tension-type headache. Current Opinion in Neurology, 1994, 7, 264-271.	1.8	48
149	A naturalistic glyceryl trinitrate infusion migraine model in the rat. Cephalalgia, 2012, 32, 73-84.	1.8	48
150	Vestibular migraine: Diagnostic criteria (Update)1. Journal of Vestibular Research: Equilibrium and Orientation, 2022, 32, 1-6.	0.8	48
151	Peptide-containing nerve fibres in human extracranial tissue: a morphological basis for neuropeptide involvement in extracranial pain?. Pain, 1986, 27, 391-399.	2.0	47
152	Quantitative surface EMG of pericranial muscles in headache. A population study. Electroencephalography and Clinical Neurophysiology - Evoked Potentials, 1994, 93, 335-344.	2.0	47
153	Implications of Clinical Subtypes of Migraine With Aura. Headache, 2006, 46, 286-297.	1.8	47
154	NXN-188, a selective nNOS inhibitor and a 5-HT _{1B/1D} receptor agonist, inhibits CGRP release in preclinical migraine models. Cephalalgia, 2013, 33, 87-100.	1.8	47
155	Drug abuse in migraine patients. Pain, 1984, 19, 81-86.	2.0	46
156	Dipyridamole Dilates Large Cerebral Arteries Concomitant to Headache Induction in Healthy Subjects. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 1372-1379.	2.4	46
157	The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation. European Journal of Pharmacology, 2001, 420, 55-65.	1.7	46
158	Part II: Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients. Cephalalgia, 2017, 37, 136-147.	1.8	46
159	Methodological Aspects of Drug Trials in Migraine. pp 204–215. Neuroepidemiology, 1985, 4, 204-215.	1.1	45
160	Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries. European Journal of Pharmacology, 2004, 489, 93-100.	1.7	44
161	Prostacyclin (epoprostenol) induces headache in healthy subjects. Pain, 2008, 139, 106-116.	2.0	44
162	Chronic versus episodic migraine: The 15â€day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache, 2021, 61, 992-1003.	1.8	44

#	Article	IF	CITATIONS
163	Publication committees in clinical trials in headache. Cephalalgia, 2012, 32, 86-86.	1.8	43
164	Genome-Wide Association Study Identifies Four Loci Associated with Eruption of Permanent Teeth. PLoS Genetics, 2011, 7, e1002275.	1.5	42
165	Algesia and local responses induced by neurokinin A and substance P in human skin and temporal muscle. Peptides, 1989, 10, 1147-1152.	1.2	41
166	Role of endothelium and nitric oxide in histamine-induced responses in human cranial arteries and detection of mRNA encoding H1 - and H2 -receptors by RT-PCR. British Journal of Pharmacology, 1997, 121, 41-48.	2.7	41
167	PACAP-38 infusion causes sustained vasodilation of the middle meningeal artery in the rat: Possible involvement of mast cells. Cephalalgia, 2014, 34, 877-886.	1.8	41
168	Heterogenous migraine aura symptoms correlate with visual cortex functional magnetic resonance imaging responses. Annals of Neurology, 2017, 82, 925-939.	2.8	41
169	Targeting CGRP via receptor antagonism and antibody neutralisation in two distinct rodent models of migraine-like pain. Cephalalgia, 2019, 39, 1827-1837.	1.8	41
170	The Copenhagen Acute Headache Clinic: Organization, Patient Material and Treatment Results. Headache, 1979, 19, 223-227.	1.8	40
171	Von Frey testing revisited: Provision of an online algorithm for improved accuracy of 50% thresholds. European Journal of Pain, 2020, 24, 783-790.	1.4	40
172	No central action of CGRP antagonising drugs in the GTN mouse model of migraine. Cephalalgia, 2020, 40, 924-934.	1.8	40
173	β-Eddorphin and ACTH in Plasma During Attacks of Common and Classic Migraine. Cephalalgia, 1985, 5, 177-182.	1.8	39
174	Effect of two novel CGRP-binding compounds in a closed cranial window rat model. European Journal of Pharmacology, 2007, 567, 117-124.	1.7	39
175	Association between neurovascular contact and clinical characteristics in classical trigeminal neuralgia: A prospective clinical study using 3.0 Tesla MRI. Cephalalgia, 2015, 35, 1077-1084.	1.8	39
176	The Effect of Single Dose Ergotamine Tartrate on Peripheral Arteries in Migraine Patients: Methodological Aspects and Time Effect Curve. Acta Pharmacologica Et Toxicologica, 1980, 47, 151-156.	0.0	38
177	Antimigraine Efficacy of Telcagepant Based on Patient's Historical Triptan Response. Headache, 2011, 51, 64-72.	1.8	38
178	Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat. European Journal of Pharmacology, 2011, 670, 186-194.	1.7	38
179	Quantitative sensory testing in classical trigeminal neuralgia—a blinded study in patients with and without concomitant persistent pain. Pain, 2016, 157, 1407-1414.	2.0	38
180	Histamine and migraine revisited: mechanisms and possible drug targets. Journal of Headache and Pain, 2019, 20, 30.	2.5	38

#	Article	IF	CITATIONS
181	The PACAP pathway is independent of CGRP in mouse models of migraine: possible new drug target?. Brain, 2022, 145, 2450-2460.	3.7	38
182	Cerebral Apoplexy (Stroke) Treated With or Without Prolonged Artificial Hyperventilation: 2. Cerebrospinal Fluid Acid-Base Balance and Intracranial Pressure. Stroke, 1973, 4, 620-631.	1.0	37
183	Exteroceptive Suppression Periods in Jaw-Closing Muscles. Variability and Relation to Experimental Pain and Sustained Muscle Contraction. Cephalalgia, 1993, 13, 184-191.	1.8	37
184	A dose?response study of nitric oxide synthase inhibition in different vascular beds in man. European Journal of Clinical Pharmacology, 2003, 59, 499-505.	0.8	37
185	Mechanisms of glyceryl trinitrate provoked mast cell degranulation. Cephalalgia, 2015, 35, 1287-1297.	1.8	37
186	Animal models of pain and migraine in drug discovery. Drug Discovery Today, 2017, 22, 1103-1111.	3.2	37
187	Whole transcriptome expression of trigeminal ganglia compared to dorsal root ganglia in Rattus Norvegicus. Neuroscience, 2017, 350, 169-179.	1.1	37
188	Nitric oxide synthase (NOS) in the trigeminal vascular system and other brain structures related to pain in rats. Neuroscience Letters, 2010, 484, 192-196.	1.0	36
189	Trigger factors for familial hemiplegic migraine. Cephalalgia, 2011, 31, 1274-1281.	1.8	36
190	Levcromakalim, an Adenosine Triphosphate‣ensitive Potassium Channel Opener, Dilates Extracerebral but not Cerebral Arteries. Headache, 2019, 59, 1468-1480.	1.8	36
191	Effervescent ASA Versus Solid ASA in the Treatment of Tension Headache. A Double-Blind, Placebo Controlled Study. Headache, 1987, 27, 90-95.	1.8	35
192	Plasma and cerebrospinal fluid β-endorphin in chronic tension-type headache. Pain, 1992, 51, 163-168.	2.0	35
193	Persistent idiopathic facial pain – a prospective systematic study of clinical characteristics and neuroanatomical findings at 3.0 Tesla MRI. Cephalalgia, 2017, 37, 1231-1240.	1.8	35
194	Twoâ€Hour CGRP Infusion Causes Gastrointestinal Hyperactivity: Possible Relevance for CGRP Antibody Treatment. Headache, 2020, 60, 929-937.	1.8	35
195	Small arteries can be accurately studied in vivo, using high frequency ultrasound. Ultrasound in Medicine and Biology, 1993, 19, 717-725.	0.7	34
196	IHS Classification: Present and Future. Cephalalgia, 1993, 13, 94-94.	1.8	34
197	Allelic variation in the serotonin 5-HT2C receptor gene and migraine. NeuroReport, 1997, 8, 2651-2563.	0.6	34
198	Inheritance of chronic tension-type headache investigated by complex segregation analysis. Human Genetics, 1998, 102, 138-140.	1.8	34

#	Article	IF	CITATIONS
199	Role of K _{ATP} Channels in Cephalic Vasodilatation Induced by Calcitonin Geneâ€Related Peptide, Nitric Oxide, and Transcranial Electrical Stimulation in the Rat. Headache, 2008, 48, 1202-1213.	1.8	34
200	Evidence for CGRP reâ€uptake in rat dura mater encephali. British Journal of Pharmacology, 2010, 161, 1885-1898.	2.7	34
201	The influence of genetic constitution on migraine drug responses. Cephalalgia, 2016, 36, 624-639.	1.8	34
202	Cross-trait analyses with migraine reveal widespread pleiotropy and suggest a vascular component to migraine headache. International Journal of Epidemiology, 2020, 49, 1022-1031.	0.9	34
203	Migraine and regional cerebral blood flow. Trends in Neurosciences, 1985, 8, 318-321.	4.2	33
204	Understanding the Biologic Basis of Migraine. New England Journal of Medicine, 1994, 331, 1713-1714.	13.9	33
205	Presence and vascular pharmacology of KATP channel subtypes in rat central and peripheral tissues. European Journal of Pharmacology, 2010, 637, 109-117.	1.7	33
206	The effect of sumatriptan on cephalic arteries: A 3T MR-angiography study in healthy volunteers. Cephalalgia, 2013, 33, 1009-1016.	1.8	33
207	Migraine: a research field matured for the basic neurosciences. Trends in Neurosciences, 1991, 14, 3-5.	4.2	32
208	The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. Journal of Headache and Pain, 2012, 13, 271-275.	2.5	32
209	Explicit diagnostic criteria for transient ischemic attacks to differentiate it from migraine with aura. Cephalalgia, 2018, 38, 1463-1470.	1.8	32
210	ATP sensitive potassium (K _{ATP}) channel inhibition: A promising new drug target for migraine. Cephalalgia, 2020, 40, 650-664.	1.8	32
211	Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description. Journal of Headache and Pain, 2021, 22, 78.	2.5	32
212	Effect of CGRP and sumatriptan on the BOLD response in visual cortex. Journal of Headache and Pain, 2012, 13, 159-166.	2.5	31
213	Migraine before rupture of intracranial aneurysms. Journal of Headache and Pain, 2013, 14, 15.	2.5	31
214	Sources of Variability of Resting Cerebral Blood Flow in Healthy Subjects: A Study Using ¹³³ Xe SPECT Measurements. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 787-792.	2.4	31
215	Part I: Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine. Cephalalgia, 2017, 37, 125-135.	1.8	31
216	Prognostic factors for outcome of microvascular decompression in trigeminal neuralgia: A prospective systematic study using independent assessors. Cephalalgia, 2019, 39, 197-208.	1.8	31

#	Article	IF	CITATIONS
217	PACAP-38 and PACAP(6–38) Degranulate Rat Meningeal Mast Cells via the Orphan MrgB3-Receptor. Frontiers in Cellular Neuroscience, 2019, 13, 114.	1.8	31
218	The CACNA1A and ATP1A2 genes are not involved in dominantly inherited migraine with aura. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 250-256.	1.1	30
219	Clinical Trial of Nimodipine for Single Attacks of Classic Migraine. Cephalalgia, 1985, 5, 125-131.	1.8	29
220	Pain, wheal and flare in human forearm skin induced by bradykinin and 5-hydroxytryptamine. Peptides, 1990, 11, 1133-1138.	1.2	29
221	Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig. European Journal of Pharmacology, 2005, 521, 105-114.	1.7	29
222	Consensus Document on European Brain Research. European Journal of Neuroscience, 2011, 33, 768-818.	1.2	29
223	Lack of correlation between vasodilatation and pharmacologically induced immediate headache in healthy subjects. Cephalalgia, 2011, 31, 683-690.	1.8	29
224	Paracetamol (Acetaminophen) versus Acetylsalicylic Acid in Migraine. European Neurology, 1980, 19, 163-165.	0.6	28
225	The Role of Nitric Oxide in Migraine Pain. CNS Drugs, 1994, 2, 417-422.	2.7	28
226	A Pivotal Role of Nitric Oxide in Migraine Pain. Annals of the New York Academy of Sciences, 1997, 835, 363-372.	1.8	28
227	Coexisting typical migraine in familial hemiplegic migraine. Neurology, 2010, 74, 594-600.	1.5	28
228	Towards a reliable animal model of migraine. Cephalalgia, 2012, 32, 578-580.	1.8	28
229	Migraine polygenic risk score associates with efficacy of migraine-specific drugs. Neurology: Genetics, 2019, 5, e364.	0.9	28
230	Quantitative surface EMG of pericranial muscles. Reproducibility and variability. Electroencephalography and Clinical Neurophysiology - Evoked Potentials, 1993, 89, 1-9.	2.0	27
231	KATP channels in pig and human intracranial arteries. European Journal of Pharmacology, 2008, 601, 43-49.	1.7	27
232	Psychosocial factors associated with migraine and tension-type headache in medical students. Cephalalgia, 2017, 37, 1264-1271.	1.8	27
233	Getting away from simple muscle contraction as a mechanism of tension-type headache. Pain, 1991, 46, 123-124.	2.0	26
234	Analysis of 31 families with an apparently autosomal-dominant transmission of migraine with aura in the nuclear family. , 1997, 74, 395-397.		26

#	Article	IF	CITATIONS
235	On the methodology of drug trials in migraine with aura. Cephalalgia, 2010, 30, 1041-1048.	1.8	26
236	New plans for headache classification: ICHD-3. Cephalalgia, 2011, 31, 4-5.	1.8	26
237	Animal Migraine Models for Drug Development: Status and Future Perspectives. CNS Drugs, 2013, 27, 1049-1068.	2.7	26
238	CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine. Cephalalgia, 2021, 41, 1413-1426.	1.8	26
239	The International Classification of Headache Disorders, 2nd edition: application to practice. Functional Neurology, 2005, 20, 61-8.	1.3	26
240	Headache classification update 2004. Current Opinion in Neurology, 2004, 17, 275-282.	1.8	25
241	Factors Associated With Primary Headache According To Diagnosis, Sex, and Social Group. Headache, 2016, 56, 341-356.	1.8	25
242	Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine. Cephalalgia, 2017, 37, 114-124.	1.8	25
243	The Classification and Diagnosis of Headache Disorders. Neurologic Clinics, 1990, 8, 793-799.	0.8	24
244	Pharmacological and molecular comparison of KATP channels in rat basilar and middle cerebral arteries. European Journal of Pharmacology, 2006, 553, 254-262.	1.7	24
245	Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP. Journal of Headache and Pain, 2010, 11, 309-316.	2.5	24
246	Discrepancy between strong cephalic arterial dilatation and mild headache caused by prostaglandin D ₂ (PGD ₂). Cephalalgia, 2011, 31, 65-76.	1.8	24
247	The association between candidate migraine susceptibility loci and severe migraine phenotype in a clinical sample. Cephalalgia, 2016, 36, 615-623.	1.8	24
248	A unique inbred rat strain with sustained cephalic hypersensitivity as a model of chronic migraine-like pain. Scientific Reports, 2018, 8, 1836.	1.6	24
249	Polygenic risk score: use in migraine research. Journal of Headache and Pain, 2018, 19, 29.	2.5	24
250	Diagnostic Accuracy of the Explicit Diagnostic Criteria for Transient Ischemic Attack. Stroke, 2019, 50, 2080-2085.	1.0	24
251	Effect of hypoxia on BOLD fMRI response and total cerebral blood flow in migraine with aura patients. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 680-689.	2.4	24
252	Evidence of localized and widespread pressure pain hypersensitivity in patients with tension-type headache: A systematic review and meta-analysis. Cephalalgia, 2021, 41, 256-273.	1.8	24

#	Article	IF	CITATIONS
253	Phosphodiesterase 3 and 5 and cyclic nucleotide-gated ion channel expression in rat trigeminovascular system. Neuroscience Letters, 2006, 404, 202-207.	1.0	23
254	The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the Prostaglandin E2 human model of headache. Journal of Headache and Pain, 2011, 12, 551-559.	2.5	23
255	Pro-inflammatory and vasoconstricting prostanoid PGF _{2α} causes no headache in man. Cephalalgia, 2011, 31, 1532-1541.	1.8	23
256	Prevalence of primary headache disorders diagnosed according to ICHD-3 beta in three different social groups. Cephalalgia, 2016, 36, 579-588.	1.8	23
257	TOTAL CO ₂ , LACTATE, AND PYRUVATE IN BRAIN BIOPSIES TAKEN AFTER FREEZING THE TISSUE IN SITU. Acta Neurologica Scandinavica, 1970, 46, 141-148.	1.0	22
258	Temporal muscle blood flow in common migraine. Acta Neurologica Scandinavica, 1985, 72, 561-570.	1.0	22
259	Favourable prognosis of trigeminal neuralgia when enrolled in a multidisciplinary management program - a two-year prospective real-life study. Journal of Headache and Pain, 2019, 20, 23.	2.5	22
260	Problem areas in the International Classification of Headache Disorders, 3rd edition (beta). Cephalalgia, 2014, 34, 1193-1199.	1.8	21
261	mRNA distribution of CGRP and its receptor components in the trigeminovascular system and other pain related structures in rat brain, and effect of intracerebroventricular administration of CGRP on Fos expression in the TNC. Neuroscience Letters, 2014, 559, 99-104.	1.0	21
262	ICHD-3 is significantly more specific than ICHD-3 beta for diagnosis of migraine with aura and with typical aura. Journal of Headache and Pain, 2020, 21, 2.	2.5	21
263	Electromyography of pericranial muscles during treatment of spontaneous common migraine attacks. Pain, 1982, 14, 137-147.	2.0	20
264	Characterization of 5-hydroxytryptamine receptors in human temporal arteries: Comparison between migraine sufferers and nonsufferers. Annals of Neurology, 1982, 12, 272-277.	2.8	20
265	Increase in self-reported migraine prevalence in the Danish adult population: a prospective longitudinal population-based study. BMJ Open, 2012, 2, e000962.	0.8	20
266	Migraine with brainstem aura: defining the core syndrome. Brain, 2019, 142, 3868-3875.	3.7	20
267	Headache at onset of firstâ€ever ischemic stroke: Clinical characteristics and predictors. European Journal of Neurology, 2021, 28, 852-860.	1.7	20
268	The effect of sodium nitroprusside on cerebral hemodynamics and headache in healthy subjects. Cephalalgia, 2013, 33, 301-307.	1.8	19
269	Carbon monoxide may be an important molecule in migraine and other headaches. Cephalalgia, 2014, 34, 1169-1180.	1.8	19
270	CGRP infusion in unanesthetized rats increases expression of c-Fos in the nucleus tractus solitarius and caudal ventrolateral medulla, but not in the trigeminal nucleus caudalis. Cephalalgia, 2015, 35, 220-233.	1.8	19

#	Article	IF	CITATIONS
271	Family studies to find rare high risk variants in migraine. Journal of Headache and Pain, 2017, 18, 32.	2.5	19
272	Prospective testing of ICHD-3 beta diagnostic criteria for migraine with aura and migraine with typical aura in patients with transient ischemic attacks. Cephalalgia, 2018, 38, 561-567.	1.8	19
273	Action of some pericranial muscles during provoked attacks of common migraine. Pain, 1982, 14, 121-135.	2.0	18
274	Field-testing of the ICHD-3 beta diagnostic criteria for classical trigeminal neuralgia. Cephalalgia, 2015, 35, 291-300.	1.8	18
275	Extracranial activation of ATP-sensitive potassium channels induces vasodilation without nociceptive effects. Cephalalgia, 2019, 39, 1789-1797.	1.8	18
276	Habitual sleep disturbances and migraine: a Mendelian randomization study. Annals of Clinical and Translational Neurology, 2020, 7, 2370-2380.	1.7	18
277	Histamine Receptors in the Isolated Human Middle Meningeal Artery. A Comparison with Cerebral and Temporal Arteries. Cephalalgia, 1991, 11, 183-188.	1.8	17
278	Effect of Histamine on Regional Cerebral Blood Flow in Man. Cephalalgia, 1982, 2, 15-18.	1.8	16
279	Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate. Journal of Headache and Pain, 2008, 9, 215-220.	2.5	16
280	Functional and molecular characterization of prostaglandin E2 dilatory receptors in the rat craniovascular system in relevance to migraine. Cephalalgia, 2010, 30, 1110-1122.	1.8	16
281	Towards a pragmatic human migraine model for drug testing: 2. Isosorbide-5-mononitrate in healthy individuals. Cephalalgia, 2017, 37, 11-19.	1.8	16
282	New International Headache Classification. Neuroepidemiology, 1989, 8, 53-55.	1.1	15
283	Future possibilities in migraine genetics. Journal of Headache and Pain, 2012, 13, 505-511.	2.5	15
284	The Yekaterinburg headache initiative: an interventional project, within the Global Campaign against Headache, to reduce the burden of headache in Russia. Journal of Headache and Pain, 2013, 14, 101.	2.5	15
285	Acute headache and persistent headache attributed to cervical artery dissection: Field testing of ICHD-III beta. Cephalalgia, 2014, 34, 712-716.	1.8	15
286	Infusion of low dose glyceryl trinitrate has no consistent effect on burrowing behavior, running wheel activity and light sensitivity in female rats. Journal of Pharmacological and Toxicological Methods, 2016, 80, 43-50.	0.3	15
287	From ICHD-3 beta to ICHD-3. Cephalalgia, 2016, 36, 401-402.	1.8	15
288	Effect of TRPA1 activator allyl isothiocyanate (AITC) on rat dural and pial arteries. Pharmacological Reports, 2019, 71, 565-572.	1.5	15

#	Article	IF	CITATIONS
289	Functional gene networks reveal distinct mechanisms segregating in migraine families. Brain, 2020, 143, 2945-2956.	3.7	15
290	No additive effect of combining sumatriptan and olcegepant in the GTN mouse model of migraine. Cephalalgia, 2021, 41, 329-339.	1.8	15
291	The electrical potential difference and impedance between CSF and blood in unanesthetized man. Scandinavian Journal of Clinical and Laboratory Investigation, 1978, 38, 203-207.	0.6	14
292	Cost of disorders of the brain in Denmark. Nordic Journal of Psychiatry, 2008, 62, 114-120.	0.7	14
293	PDE9A, PDE10A, and PDE11A expression in rat trigeminovascular pain signalling system. Brain Research, 2009, 1281, 25-34.	1.1	14
294	Toward a pragmatic migraine model for drug testing: 1. Cilostazol in healthy volunteers. Cephalalgia, 2016, 36, 172-178.	1.8	14
295	Cilostazol induces C-fos expression in the trigeminal nucleus caudalis and behavioural changes suggestive of headache with the migraine-like feature photophobia in female rats. Cephalalgia, 2018, 38, 452-465.	1.8	14
296	The Global Campaign turns 18: a brief review of its activities and achievements. Journal of Headache and Pain, 2022, 23, 49.	2.5	14
297	Effects of Ergot Alkaloids (Hydergine®) on Cerebral Haemodynamics in Man. Acta Pharmacologica Et Toxicologica, 1972, 31, 75-85.	0.0	13
298	Effect of Serotonin on Regional Cerebral Blood Flow (rCBF) in Man. Cephalalgia, 1981, 1, 7-10.	1.8	13
299	No release of interstitial glutamate in experimental human model of muscle pain. European Journal of Pain, 2005, 9, 337-337.	1.4	13
300	Licence for Botox in so-called chronic migraine. Lancet, The, 2010, 376, 1825-1826.	6.3	13
301	Prostaglandin E2 receptor expression in the rat trigeminal-vascular system and other brain structures involved in pain. Neuroscience Letters, 2012, 506, 64-69.	1.0	13
302	The quality of diagnosis and management of migraine and tension-type headache in three social groups in Russia. Cephalalgia, 2017, 37, 225-235.	1.8	13
303	Nosographic analysis of osmophobia and field testing of diagnostic criteria including osmophobia. Cephalalgia, 2019, 39, 38-43.	1.8	13
304	Methodology of clinical trials in migraine. , 1988, , 85-109.		13
305	Consensus document on European brain research. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77 Suppl 1, i1-49.	0.9	13
306	Are Classical and Common Migraine Different Entities?. Headache, 1985, 25, 213-213.	1.8	12

#	Article	IF	CITATIONS
307	Field-testing of the ICHD-3 beta/proposed ICD-11 diagnostic criteria for migraine with aura. Cephalalgia, 2015, 35, 748-756.	1.8	12
308	Comparing migraine with and without aura to healthy controls using RNA sequencing. Cephalalgia, 2019, 39, 1435-1444.	1.8	12
309	Sentinel headache as a warning symptom of ischemic stroke. Journal of Headache and Pain, 2020, 21, 70.	2.5	12
310	Sumatriptan Does Not Antagonize CGRPâ€Induced Symptoms in Healthy Volunteers. Headache, 2020, 60, 665-676.	1.8	12
311	Low adherence to the guideline for the acute treatment of migraine. Scientific Reports, 2022, 12, 8487.	1.6	12
312	Headache Resembling Tension-Type Headache as the Single Manifestation of Lyme Neuroborreliosis. Cephalalgia, 1993, 13, 207-209.	1.8	11
313	Regional Cerebral Blood Flow and Oxygen Metabolism During Migraine with and Without Aura. Cephalalgia, 1998, 18, 2-2.	1.8	11
314	Classification of Headache Disorders. Seminars in Neurology, 2006, 26, 157-162.	0.5	11
315	Molecular studies of BKCa channels in intracranial arteries: presence and localization. Cell and Tissue Research, 2008, 334, 359-369.	1.5	11
316	Molecular investigations of BKCa channels and the modulatory β-subunits in porcine basilar and middle cerebral arteries. Journal of Molecular Histology, 2009, 40, 87-97.	1.0	11
317	Can nitric oxide induce migraine in normal individuals?. Cephalalgia, 2015, 35, 1125-1129.	1.8	11
318	Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers. Peptides, 2015, 74, 33-42.	1.2	11
319	Cilostazol induced migraine does not respond to sumatriptan in a double blind trial. Journal of Headache and Pain, 2018, 19, 11.	2.5	11
320	Familial analysis reveals rare risk variants for migraine in regulatory regions. Neurogenetics, 2020, 21, 149-157.	0.7	11
321	Smooth muscle ATP-sensitive potassium channels mediate migraine-relevant hypersensitivity in mouse models. Cephalalgia, 2022, 42, 93-107.	1.8	11
322	The in vivo effect of adrenomedullin on rat dural and pial arteries. European Journal of Pharmacology, 2006, 538, 101-107.	1.7	10
323	Arterial Response to Ergotamine Tartrate in Abusing and Nonâ€abusing Migraine Patients. Acta Pharmacologica Et Toxicologica, 1981, 48, 69-72.	0.0	10
324	The Future of Headache Classification and Classification Research. Cephalalgia, 2009, 29, 1240-1241.	1.8	10

#	Article	IF	CITATIONS
325	Pharmacological and expression profile of the prostaglandin I2 receptor in the rat craniovascular system. Vascular Pharmacology, 2011, 55, 50-58.	1.0	10
326	CGRP in migraine. Cephalalgia, 2011, 31, 638-638.	1.8	10
327	Association of acetazolamide infusion with headache and cranial artery dilation in healthy volunteers. Pain, 2014, 155, 1649-1658.	2.0	10
328	How Well Does the ICHD 3 (Beta) Help in Real-Life Migraine Diagnosis and Management?. Current Pain and Headache Reports, 2016, 20, 66.	1.3	10
329	Effect of PGD2 on middle meningeal artery and mRNA expression profile of L-PGD2 synthase and DP receptors in trigeminovascular system and other pain processing structures in rat brain. Pharmacological Reports, 2017, 69, 50-56.	1.5	10
330	Higher burden of rare frameshift indels in genes related to synaptic transmission separate familial hemiplegic migraine from common types of migraine. Journal of Medical Genetics, 2020, 57, 610-616.	1.5	10
331	Chronic migraine: Genetics or environment?. European Journal of Neurology, 2021, 28, 1726-1736.	1.7	10
332	Changes in the gene expression profile during spontaneous migraine attacks. Scientific Reports, 2021, 11, 8294.	1.6	10
333	Regional Cerebral Blood Flow during Attacks and When Free of Symptoms in a Large Group of Migraine Patients. Cephalalgia, 1989, 9, 29-30.	1.8	9
334	Activation of PARâ€2 Elicits NOâ€Dependent and CGRPâ€Independent Dilation of the Dural Artery. Headache, 2010, 50, 1017-1030.	1.8	9
335	Genotype–phenotype correlation in migraine without aura focusing on the rs1835740 variant on 8q22.1. Journal of Headache and Pain, 2012, 13, 21-27.	2.5	9
336	Carbon monoxide inhalation induces headache in a human headache model. Cephalalgia, 2018, 38, 697-706.	1.8	9
337	Twenty-five years of triptans – a nationwide population study. Cephalalgia, 2021, 41, 894-904.	1.8	9
338	Beta-Adrenergic Effects on Cerebral Circulation. Cephalalgia, 1986, 6, 41-46.	1.8	8
339	Migraine Epidemiology. Cephalalgia, 1993, 13, 214-217.	1.8	8
340	Expression of BKCa channels and the modulatory Î ² -subunits in the rat and porcine trigeminal ganglion. Brain Research, 2009, 1292, 1-13.	1.1	8
341	Laboratory tests of headache disorders – dawn of a new era?. Cephalalgia, 2016, 36, 1268-1290.	1.8	8
342	Headache in transient ischemic attacks. Journal of Headache and Pain, 2018, 19, 60.	2.5	8

#	Article	IF	CITATIONS
343	Predicting treatment response using pharmacy register in migraine. Journal of Headache and Pain, 2019, 20, 31.	2.5	8
344	RNA Sequencing of Trigeminal Ganglia in Rattus Norvegicus after Glyceryl Trinitrate Infusion with Relevance to Migraine. PLoS ONE, 2016, 11, e0155039.	1.1	8
345	Soluble ICAM-1, demyelination, and inflammation in multiple sclerosis and acute optic neuritis. Journal of Neuroimmunology, 1998, 88, 120-127.	1.1	7
346	Evidence of a Christmas spirit network in the brain: functional MRI study. BMJ, The, 2015, 351, h6266.	3.0	7
347	Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers. Journal of Headache and Pain, 2018, 19, 71.	2.5	7
348	Diagnostic criteria for acute headache attributed to ischemic stroke and for sentinel headache before ischemic stroke. Journal of Headache and Pain, 2022, 23, 11.	2.5	7
349	Population-based prevalence of cranial autonomic symptoms in migraine and proposed diagnostic appendix criteria. Cephalalgia, 2022, 42, 1160-1171.	1.8	7
350	Chlormezanone in the Treatment of Migraine Attacks: A Double Blind Comparison with Diazepam and Placebo. Cephalalgia, 1982, 2, 205-210.	1.8	6
351	CLUSTER HEADACHE ASSOCIATED WITH PRIMARY HYPERLIPIDEMIA. Acta Neurologica Scandinavica, 2009, 56, 461-464.	1.0	6
352	Are migraine endophenotypes needed?. Nature Reviews Neurology, 2016, 12, 320-321.	4.9	6
353	Selective cephalic upregulation of p-ERK, CamKII and p-CREB in response to glyceryl trinitrate infusion. Cephalalgia, 2018, 38, 1057-1070.	1.8	6
354	European Brain Council: partnership to promote European and national brain research. Trends in Neurosciences, 2006, 29, 493-495.	4.2	5
355	5-Hydroxyptryptamine 1F (5-HT _{1F}) receptor agonism. A possible new treatment principle for acute migraine attacks. Cephalalgia, 2010, 30, 1157-1158.	1.8	5
356	A neural pathway for photophobia in migraine. Nature Reviews Neurology, 2010, 6, 241-242.	4.9	5
357	Investigation of SNP rs2060546 Immediately Upstream to NTN4 in a Danish Gilles de la Tourette Syndrome Cohort. Frontiers in Neuroscience, 2016, 10, 531.	1.4	5
358	Transcriptomic profiling of trigeminal nucleus caudalis and spinal cord dorsal horn. Brain Research, 2018, 1692, 23-33.	1.1	5
359	Carbon monoxide inhalation induces headache but no migraine in patients with migraine without aura. Cephalalgia, 2018, 38, 1940-1949.	1.8	5
360	Increasing the effect of triptans in migraine. Lancet, The, 2006, 368, 1313-1314.	6.3	4

#	Article	IF	CITATIONS
361	The Danish Headache Center: From origin to full development. Cephalalgia, 2017, 37, 5-6.	1.8	4
362	New diagnostic criteria for headache attributed to transient ischemic attacks. Journal of Headache and Pain, 2019, 20, 97.	2.5	4
363	Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients. Cephalalgia, 2020, 40, 842-850.	1.8	4
364	Prevalence and socio-demographic characteristics of persons who have never had a headache among healthy voluntary blood donors – a population-based study. Cephalalgia, 2020, 40, 1055-1062.	1.8	4
365	Absence of HTLV-I DNA in Blood from Patients with Multiple Sclerosis. AIDS Research and Human Retroviruses, 1990, 6, 1219-1219.	0.5	3
366	Botulinum Toxin in Headache Treatment: The End of The Road?: Reply. Cephalalgia, 2007, 27, 468-468.	1.8	3
367	No effect of pure oxygen inhalation on headache induced by glyceryl trinitrate. Journal of Headache and Pain, 2010, 11, 93-95.	2.5	3
368	Migraine headache: Pathogenesis and treatment. Pain, 1987, 30, S2-S3.	2.0	2
369	Ophthalmoplegic Migraine: Diagnostic Criteria, Incidence of Hospitalization and Possible Etiology. Cephalalgia, 1989, 9, 252-253.	1.8	2
370	Headache and Changes in the Diameter of the Radial Artery during 7 Hours Intravenous Nitroglycerin Infusion. Cephalalgia, 1989, 9, 82-83.	1.8	2
371	Activities in the Danish Year of the Brain 1997. European Journal of Neurology, 1998, 5, 619-624.	1.7	2
372	Are headache disorders caused by neurobiological mechanisms?. Current Opinion in Neurology, 2006, 19, 277-280.	1.8	2
373	Mechanism of Ergotamineâ€induced Decrease of Peripheral Systolic Blood Pressure in Man. Acta Pharmacologica Et Toxicologica, 1982, 51, 122-125.	0.0	2
374	Implementing the International Classification of Headache Disorders, 2nd edition (ICHD-II). Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 147-159.	1.0	2
375	Calcitonin gene-related peptide — beyond migraine prophylaxis. Nature Reviews Neurology, 2019, 15, 562-564.	4.9	2
376	Localization of TRPA1 channels and characterization of TRPA1 mediated responses in dural and pial arteries in vivo after intracarotid infusion of Na2S. Cephalalgia, 2020, 40, 1310-1320.	1.8	2
377	Reply: Hyperpolarization through ATP-sensitive potassium channels; relevance to migraine pathology. Brain, 2020, 143, e14-e14.	3.7	2
378	Explicit Diagnostic Criteria for Transient Ischemic Attacks Used in the Emergency Department Are Highly Sensitive and Specific. Cerebrovascular Diseases, 2021, 50, 62-67.	0.8	2

#	Article	IF	CITATIONS
379	Pain sensitivity in men who have never experienced a headache: an observer blinded case control study. Journal of Headache and Pain, 2021, 22, 134.	2.5	2
380	Calcium Entry Blockers in the Prophylaxis of Migraine. Annals of the New York Academy of Sciences, 1988, 522, 720-722.	1.8	1
381	Treatment of Migraine with Calcium Entry Blockers. Progress in Basic and Clinical Pharmacology, 1989, 2, 143-154.	0.1	1
382	Interictal Spect Studies of rCBF in Migraine Patients Suggesting Abnormal, Patchy Vascular Regulation Cephalalgia, 1991, 11, 40-41.	1.8	1
383	Dilatation of the Middle Cerebral Artery: A Mechanism of Migraine Pain and its Reversal by I.V. Injection of a 5-HT1Like Receptor Agonist (Sumatriptan) Cephalalgia, 1991, 11, 7-8.	1.8	1
384	Drs. Rasmussen, Jensen and Olesen Reply. Headache, 1992, 32, 56-56.	1.8	1
385	Year of the Brain in European countries. Background and organization. European Journal of Neurology, 1998, 5, 325-328.	1.7	1
386	New developments for the European Journal of Neurology. European Journal of Neurology, 2001, 8, 289-289.	1.7	1
387	Collaboration to promote neurological research—the European Brain Council experience. Nature Clinical Practice Neurology, 2007, 3, 298-299.	2.7	1
388	Let's Put "Mixed Headache" to Rest: A Response. Headache, 2007, 47, 98.	1.8	1
389	COMMON MIGRAINE AND TEMPORAL MUSCLE BLOOD FLOW. Acta Neurologica Scandinavica, 2009, 69, 254-255.	1.0	1
390	Intracranial and extracranial arteries in migraine – Authors' reply. Lancet Neurology, The, 2013, 12, 848-849.	4.9	1
391	Highlights in headache research in 2013. Lancet Neurology, The, 2014, 13, 5-7.	4.9	1
392	Letter to the editor regarding proposed new diagnostic criteria for migraine. Cephalalgia, 2020, 40, 415-418.	1.8	1
393	Tension-Type Headache. , 2003, , 23-30.		1
394	Vasoactive intestinal polypeptide is unlikely to be a target for headache and migraine treatment. , 2008, , 121-128.		1
395	Differential expression of BKâ€channel isoforms and betaâ€subunits in rat neuroâ€vascular tissues. FASEB Journal, 2008, 22, 744.19.	0.2	1
396	Barriers to Care. Headache, 2019, , 173-183.	0.2	1

#	Article	IF	CITATIONS
397	Personal view: Modelling pain mechanisms of migraine without aura. Cephalalgia, 0, , 033310242211115.	1.8	1
398	The practicing physician's approach to headache. Pain, 1983, 16, 400.	2.0	0
399	Methodological Aspects of Drug Trials in Migraine. pp 216–226. Neuroepidemiology, 1985, 4, 216-226.	1.1	0
400	Dynorphin-Immunoreactivity In Plasma During Migraine Attacks. Cephalalgia, 1987, 7, 232-233.	1.8	0
401	Clinical Characteristics of Migraine and Episodic Tension-Type Headache in Relation to Old and New Diagnostic Criteria. Cephalalgia, 1989, 9, 264-265.	1.8	0
402	Neurokinin A and Temporal Muscle Blood Flow. Cephalalgia, 1989, 9, 74-75.	1.8	0
403	Epidemiology of Migraine, Tension-Type Headache and Other Headache Disorders Using the New IHS-Criteria. Cephalalgia, 1989, 9, 250-251.	1.8	0
404	Causes of Headache. Cephalalgia, 1989, 9, 167-169.	1.8	0
405	Advanced EMG-Evaluation of Headache according to the IHS-Classification. A Population Based Study. Cephalalgia, 1989, 9, 307-308.	1.8	0
406	Pressure-sensitive devices. Pain, 1995, 62, 250.	2.0	0
407	International Headache Research Seminars. Cephalalgia, 1996, 16, 344-345.	1.8	0
408	Reply: To the editor. Arthritis and Rheumatism, 1997, 40, 2276-2277.	6.7	0
409	Professor Luigi Amaducci 1932-1998. European Journal of Neurology, 1998, 5, 117-118.	1.7	0
410	Disorders of the brain: costs, recent progress and future possibilities. European Journal of Neurology, 1998, 5, 425-430.	1.7	0
411	European Federation of Neurological Societies (EFNS) Guideline Papers. European Journal of Neurology, 1999, 6, 257-258.	1.7	0
412	PDE9A, PDE10A, and PDE11A expression in rat trigeminovascular pain signalling system: role in pathogenesis of migraine?. BMC Pharmacology, 2007, 7, .	0.4	0
413	FOCAL CEREBRAL BLOOD FLOW, REACTIVITY OF CEREBRAL BLOOD VESSELS AND CEREBRAL OXYDATIVE METABOLISM IN CERTAIN GROUPS OF PATIENTS WITH ORGANIC DEMENTIA. Acta Neurologica Scandinavica, 2009, 46, 76-76.	1.0	0
414	CHLORMEZANONE IN THE TREATMENT OF MIGRAINE ATTACKS. A DOUBLE BLIND COMPARISON WITH DIAZEPAM AND PLACEBO Acta Neurologica Scandinavica, 2009, 65, 81-82.	1.0	0

#	Article	IF	CITATIONS
415	Answer to the letter from Joanna Zakrzewska. Journal of Headache and Pain, 2012, 13, 173-173.	2.5	0
416	Comment on Headache Following Intracranial Neuroendovascular Procedures. Headache, 2013, 53, 383-384.	1.8	0
417	Reply to the comments about our article "Headache at onset of firstâ€ever ischemic stroke: Clinical characteristics and predictors― European Journal of Neurology, 2021, 28, e60-e62.	1.7	0
418	Nitric Oxide, Perivascular Neural Transmission, and Migraine. , 2000, , 199-215.		0
419	Cerebral Blood Flow Changes in Migraine: Their Possible Correspondence to the Perfusion Changes of Spreading Cortical Depression. , 1985, , 87-96.		0
420	Migraine with Typical Aura. Headache, 2015, , 5-10.	0.2	0
421	The Importance of Some Possible Somatic and Environmental Risk Factors for the Development of Migraine. Journal of Neurology Research, 2015, 5, 193-198.	0.2	0
422	Headache provocation by nitric oxide in men who have never experienced a headache. Cephalalgia, 2021, , 033310242110600.	1.8	0